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(EORTC QLQ-C30 & H&N35), and penetration aspiration scale 
(PAS) scores for modified barium swallow studies. 
 
Results: The study population is 43 patients. The pCR rate 
was 86% (37/43). All 6 non-pCR cases were limited to 
microscopic foci of residual cancer: 1 primary site, 5 nodal. 
All patients are alive with no evidence of disease (median 
follow-up 21.3 months, range 4-41 months). Thirty-eight 
patients had a follow-up of at least one year. The incidence 
of acute CTCAE Grade 3/4 toxicity and PRO-CTCAE 
severe/very severe symptoms were: mucositis 34%/45%, pain 
5%/48%, nausea 18%/52%, vomiting 5%/34%, dysphagia 
39%/55%, and xerostomia 2%/75%. Grade 3/4 hematological 
toxicities were 11%. Mean pre and 6 month post CRT EORTC 
QOL scores were: Global 80/71 (lower worse), Pain (mouth, 
jaw, throat) 19/21 (higher worse), Swallowing 11/16, 
Coughing 17/26, Dry Mouth 16/68, and Sticky Saliva 6/49. Six 
months post CRT mean PRO-CTCAE scores for swallowing and 
dry mouth were mild and moderate, respectively. No patients 
reported their swallowing or dry mouth symptoms to be 
severe or very severe. 39% of patients required a feeding 
tube (none permanent) for a median of 15 weeks (5 - 22 
weeks). There were no significant differences in PAS scores 
for thin, pureed, and solid foods before and after CRT. 
 
Conclusion: Pathological CR rate with decreased intensity of 
therapy with 60 Gy of IMRT and weekly low-dose cisplatinum 
is very high in favorable risk OPSCC with evidence of 
decreased toxicity compared to standard therapies. 
(ClinicalTrials.gov, NCT01530997) 
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Purpose or Objective: To investigate the long-term clinical 
behavior of nasopharyngeal carcinoma (NPC) patients with 
persistently detectable plasma EBV (pEBV) DNA after curative 
radiotherapy (RT) with/without chemotherapy. 
 
Material and Methods: We screened 931 newly diagnosed 
NPC patients who finished curative RT and found 125 patients 
(13.4%) with detectable pEBV DNA one week after finishing 
RT. The clinical characteristics, treatment modality, 
subsequent failure patterns and survivals were analyzed. 
 
Results: The levels of post-RT pEBV DNA for the studied 
population were in a very lower copy number (median 21, 
interquartile range 8-206 copies/mL). After a minimal follow-
up of 52 months, the subsequent relapse rate was 64.8% 
(81/125) with distant failure predominantly and the median 
time to progression is 20 months for all 125 patients. Thirty-
two of 39 (82.1%) patients with post-RT pEBV DNA ³ 100 
copies/ml developed tumor relapse later, whereas 57.0% 
(49/86) patients with post-RT pEBV DNA < 100 copies/ml had 
tumor relapse (P=0.0065). The 5-year rates of overall survival 
(OS) were 20.5% and 62.9% for the patients with post-RT viral 
load ³ and < 100 copies/mL (HR, 0.22; 95% CI, 0.12 to 0.38; 
P<0.0001). Patients who received adjuvant chemotherapy 
(AdjCT) with oral tegafur-uracil experienced significant 
reduction in distant failures (66.2% vs. 31.6%; P=0.0001) but 
similar locoregional recurrences (P=0.234). The 5-year OS 
rates were 69.4% for the patients who received AdjCT 
compared with 33.2% for those of without AdjCT (HR, 0.38; 
95% CI, 0.24 to 0.61; P<0.0001). 
 
Conclusion: NPC patients with persistently detectable pEBV 
DNA after finishing RT have a higher rate of treatment 
failure. Levels of the post-RT pEBV DNA and administration of 
AdjCT affect the final outcome. Future trial should consider 
post-RT pEBV DNA levels as a stratification factor and 
investigate the role of AdjCT for the target population. 
 
Proffered Papers: Physics 11: Dose measurement and dose 
calculation II  
 
 
OC-0455  
Development of activity pencil beam algorithm using 
nuclear reaction for innovative proton therapy 
A. Nishio-Miyatake
1Keen Medical Physics Corporation, Medical Physics Research, 
Yokohama, Japan 
1, T.N. Teiji Nishio2 
2Hiroshima University, Institute of Biomedical & Health 
Sciences, Hiroshima, Japan 
 
Purpose or Objective: Proton therapy is a form of 
radiotherapy that can be concentrated on a tumor using a 
scanned or modulated Bragg peak. To use this radiotherapy 
efficiently in a clinical context, it is necessary to evaluate 
the clinical proton-irradiated volume accurately. Therefore, 
a beam ON-LINE PET system (BOLPs) has been developed for 
activity imaging of various positron emitter nuclei generated 
from each target nucleus by target nuclear fragment 
reactions with irradiated proton beam. The purpose of this 
study is to develop an activity pencil beam (APB) algorithm 
for a simulation system for proton activated positron-
emitting imaging in proton therapy. 
 
 
 
Material and Methods: The APB algorithm was developed as 
a calculation algorithm of the activity distributions formed by 
positron emitter nuclei generated from target nuclear 
fragment reactions. Depth activity data of 12C nuclei, 16O 
nuclei, and 40Ca nuclei were measured with BOLPs after 
proton beam irradiation whose energies were 138, 179, and 
223 MeV. Measurement time was about 5 h until the 
measured activity reached the background level.  
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Results: Data of measured depth activity distributions were 
prepared using the measured depth activity data. Activity 
pencil beam kernels needed for the APB algorithm were 
constructed using the data of measured depth activity 
distributions and calculations in lateral direction. Gaussian 
form was used for the lateral distribution data to take the 
effect of multiple Coulomb scattering into consideration. 
 
Conclusion: A method of obtaining the depth activity 
distributions and the APB algorithm were developed. The 
simulation system with the APB algorithm can be used in 
clinical proton therapy. 
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Purpose or Objective: To improve precision of particle 
therapy, in vivo range verification is highly desirable. 
Methods based on prompt gamma rays emitted during 
treatment seem promising but have not yet been applied 
clinically. Here we report on the translational 
implementation as well as the worldwide first clinical 
application of prompt gamma imaging (PGI) based range 
verification. 
 
Material and Methods: Focused on the goal of translating a 
knife-edge shaped slit camera prototype into clinical 
operation, we first systematically addressed remaining 
challenges and questions. A robust energy calibration routine 
and corresponding quality assurance protocols were 
developed. Furthermore, the positioning accuracy of the 
system was determined. The slit camera, intentionally 
developed for pencil beam scanning, was applied for double 
scattered (DS) proton beams. Systematic phantom 
experiments with increasing complexity have been 
performed.  
In the next step, the knife-edge shaped slit camera was 
applied clinically to measure the spatial prompt gamma ray 
distribution during a proton treatment of a head and neck 
tumor for seven consecutive fractions. Inter-fractional 
variations of the prompt gamma profile were evaluated. For 
three fractions in-room control CTs were acquired and 
evaluated for dose relevant changes. 
 
Results: In translational phantom experiments it was shown 
that proton range shifts can be visualized with the camera 
system for DS proton irradiation, proving its applicability 
under conditions of increased neutron background. Moreover, 
prompt gamma profiles for single iso-energy layers were 
extracted by synchronizing time resolved measurements to 
the rotation of the range modulator wheel of the DS 
treatment system. Furthermore, the position precision of the 
slit camera has been determined to provisionally be 1.1 mm 
(2σ).  
With this preparatory work, the first clinical application of 
the PGI slit camera was successful. Based on the PGI 
information, inter-fractional global range variations were in 
the range of ±2 mm for all evaluated fractions. The results of 
the iso-energy layer resolved prompt gamma profile analysis 
were in consistence with the sum profile analysis. Also the 
control CT based dose reconstruction revealed negligible 
range variations of about 1.5 mm. No influence of DVH 
parameters for target volume and organs at risk was found. 
 
 
 
Conclusion: This work demonstrates for the first time that 
prompt gamma ray based range verification can be applied 
for clinical treatment of patients. Further plans include the 
continuation of the clinical study to perform systematic 
evaluations based on an appropriate patient number. With 
the translation from basic physics experiments into clinical 
operation, the authors are confident that a prompt-gamma 
ray based technology is capable of range verification and can 
be used in the near future for online quality assurance as 
well as in midterm for potential margin reduction. 
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Purpose or Objective: The importance of MRI steadily 
increases in radiation oncology not only as multimodality 
imaging device but also as an implemented online imaging 
